# Jyothy Labs share price today (Jyothy Labs Ltd, NSE: JYOTHYLAB)

> Jyothy Labs share price today: ₹188.24 at the NSE close on 3 November 2026, down 40.1% in a year. Jyothy Labs (NSE: JYOTHYLAB) is worth ₹6,909 crore, trades at a P/E of 24.3 and has closed between ₹171.91 and ₹312.35 over the past 52 weeks. > Jyothy Labs Ltd's P/E is near the low end of its own history, higher than only 7% of past readings, and its quarterly results are still getting worse. JYOTHYLAB · FMCG - Personal Care · data as of 3 November 2026. Page: https://www.sectoralpha.in/stocks/jyothy-labs-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Slowing from a peak, from the last 12 quarters
- Price: ₹188.24 (−40.1% in a year)
- P/E: 24.3× (lower than 93% of the last 11 years)
- Revenue (Jun 2026): ₹773 Cr (+2.9% on a year ago)
- Profit (Jun 2026): ₹48.0 Cr (−50.5% on a year ago)
- Operating margin: 8.0% (−9.0 points on a year ago)
- ROCE: 29%, FY26
- ROIC: 29.8%, against a 12.0% cost of capital: +17.8 points

The main question: yearly earnings per share moved −10.3% while the share price moved −40.1%. ## What is the Jyothy Labs share price today? Jyothy Labs Ltd's share price was ₹188.24 at the close on 3 November 2026. It has been falling for 99 weeks. That is 15.1% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹172 and ₹312, and at that close it sat 12% of the way up from that low. Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 4 weeks running. Over the last 11 years the share price moved +31% while the NIFTY 500 moved +251%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 9 October 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Jyothy Labs this quarter? Three changes stood out: revenue up on a year earlier for 14 quarters in a row (every quarter we can compare), lowest operating margin in 18 quarters and indian funds and insurers (DIIs) cut their stake for 4 quarters in a row. 1. Revenue up on a year earlier for 14 quarters in a row (every quarter we can compare) In the June 2026 quarter revenue was ₹773 crore, +2.9% on a year earlier. Why: Revenue rose because Fabric Care grew strongly, with value up over 14% and volume up 10%. Next results: check whether revenue excluding Pril/Fa grows at the double-digit pace management expects. From the earnings call on 12 Aug 2026. 2. Lowest operating margin in 18 quarters Operating margin was 8% in the June 2026 quarter, against 17% a year earlier. Why: Margins fell because raw material and packing costs jumped, and price increases did not fully catch up. From the earnings call on 12 Aug 2026. 3. Indian funds and insurers (DIIs) cut their stake for 4 quarters in a row From 16.1% to 9.9% of the company by the September 2026 quarter. ## What are Jyothy Labs' latest quarterly results? For April to June 2026 (the quarter ended 30 June 2026), Jyothy Labs reported revenue of ₹773 crore, up 2.9% from ₹751 crore a year earlier, and a profit of ₹48.0 crore, down 50.5% from ₹97.0 crore. ### Jyothy Labs results: April to June 2026 against a year earlier

| Measure | April to June 2026 | April to June 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹773 crore | ₹751 crore | +2.9% |
| Profit | ₹48.0 crore | ₹97.0 crore | −50.5% |
| Earnings per share | ₹1.30 | ₹2.64 | −50.8% |
| Operating margin | 8.0% | 17.0% | −9.0 points |

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). Jyothy Labs' management discussed these results on a call held on 12 August 2026; what it said is further down this page. (From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.)

## What is the Jyothy Labs share price history? Jyothy Labs closed at ₹188.24 on 3 November 2026, down 40.1% from ₹314.50 a year earlier (31 October 2025) and up 19.0% over five years. Its highest weekly close since March 2016 was ₹556.90 on 13 September 2024. ### Jyothy Labs share price: then and now

| When | Close | Change to 3 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 23 Oct 2026 | ₹175.36 | +7.3% |
| 1 month ago · 1 Oct 2026 | ₹182.91 | +2.9% |
| 6 months ago · 30 Apr 2026 | ₹265.64 | −29.1% |
| 1 year ago · 31 Oct 2025 | ₹314.50 | −40.1% |
| 3 years ago · 3 Nov 2023 | ₹362.20 | −48.0% |
| 5 years ago · 4 Nov 2021 | ₹158.15 | +19.0% |
| 10 years ago · 4 Nov 2016 | ₹174.55 | +7.8% |
| Earliest weekly close in our records · 11 Mar 2016 | ₹143.15 | +31.5% |
| Highest weekly close since March 2016 · 13 Sep 2024 | ₹556.90 | −66.2% |
| Lowest weekly close since March 2016 · 3 Apr 2020 | ₹94.25 | +99.7% |
| 52-week high (weekly close) · 7 Nov 2025 | ₹312.35 | −39.7% |
| 52-week low (weekly close) · 30 Oct 2026 | ₹171.91 | +9.5% |

Weekly closing prices, adjusted for splits and bonuses so every price is on today’s share count. Each change is the move from that price to the 3 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (562 weekly closes from 11 March 2016 to 3 November 2026.)

## What is the latest news on Jyothy Labs? 3 Nov 2026: Jyothy Labs closed at ₹188.24, up 7.3% on the week and up 2.9% on the month. 12 Aug 2026: Jyothy Labs held its results call for April to June 2026. Management guided: FY27 revenue excluding Pril/Fa expected to grow double digit. ### Earlier

- Results for April to June 2026: Revenue up 2.9% and profit down 50.5% on a year earlier. - 29 Jun 2026: ex-date for a dividend of ₹3.50 a share. ## What dividend does Jyothy Labs pay? Jyothy Labs paid ₹3.50 a share in regular dividends in the 12 months to 4 November 2026 (1 payment), a yield of 1.86% at the ₹188.24 close on 3 November 2026. The last was a dividend of ₹3.50 a share, ex-date 29 June 2026. ### Jyothy Labs dividends since 1 April 2021

| Ex-date | Dividend per share | Type |
| --- | --- | --- |
| 29 Jun 2026 | ₹3.50 | Dividend |
| 28 Aug 2025 | ₹3.50 | Dividend |
| 3 Jul 2024 | ₹3.50 | Dividend |
| 3 Jul 2023 | ₹3 | Dividend |
| 1 Jul 2022 | ₹2.50 | Dividend |
| 20 Jul 2021 | ₹4 | Dividend |

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. The record date is the same day as the ex-date for every payment here. 5 of 5 Of the last 5 financial years, years with an NSE dividend record

Yes. Jyothy Labs Ltd paid out 39% of its profit as dividends in FY26, and it paid a dividend in each of its last 13 reported years. (From the NSE corporate-actions record, read 4 November 2026.)

## What did Jyothy Labs management say on the latest results call? On the call for April to June 2026, held on 12 August 2026, Jyothy Labs' management guided: FY27 revenue excluding Pril/Fa expected to grow double digit. > “We will assess that at the relevant point in time, Ronak. Right now, we will see what we have to do, and more people are welcome to the party.”
> Jyothy, on the call for April to June 2026

### What management guided

- July to September 2026 revenue excluding Pril/Fa planned at double digit; Personal Care expected to rejoin momentum from Q2; reported growth including Pril/Fa around 5%. - FY27 high-single-digit volume growth expected throughout the year. - Total pricing actions of about 4-4.5%, with 3% flowed through Q1 and the balance expected in Q2. - FY27 operating margin likely to remain under pressure, with H2 substantially better than H1. Management’s own plans and goals, from our notes of the call. A plan is not a result. Source: [the call transcript](https://files.tijorifinance.com/insight/india/4867/Conference Call/CC-Aug26.pdf). (From the call for April to June 2026, 12 August 2026.)

## What to watch in Jyothy Labs' next results? When Jyothy Labs reports July to September 2026, these are the 4 checks that show whether the story is still on course. First: Ex-Pril/Fa Home Care growth, Exo liquid substitution and Maxo distribution - check whether early progress broadens across channels. - What to check (from the call)
- Ex-Pril/Fa Home Care growth, Exo liquid substitution and Maxo distribution - check whether early progress broadens across channels. - Margin recovery after input inflation - check whether pricing, procurement and operating leverage improve profitability progressively. - Personal Care recovery from Q2 and H2 growth trajectory - check whether the segment rejoins momentum after price and supply disruption. - Pril court proceedings and any cooling-off clarification - check for an update affecting future market availability. ## Which stock lists is Jyothy Labs on? Jyothy Labs is on 2 of our India lists: 52 week high & low and Dividend stocks. - [52 week high & low 52-week position: At 52-week low](https://www.sectoralpha.in/52-week-high-stocks-india)
- [Dividend stocks Regular dividend yield (%): 1.89](https://www.sectoralpha.in/dividend-stocks-india)

## Is Jyothy Labs profitable? Jyothy Labs Ltd earned ₹48.0 Cr of net profit in the Jun 2026 quarter, −50.5% on the same quarter a year earlier. Full-year FY26 profit was ₹333 Cr. Over 10 years profit has grown 16.1% a year on average. That is 6.2% of the quarter's revenue. The same quarter a year earlier earned ₹97.0 Cr. For the full year, FY26 profit was ₹333 Cr (−10.2% on the year before). Why profit moved: revenue changed +2.9% on a year earlier and the margin moved −9.0 percentage points. Sales did the work while the margin got thinner. On average over the last four quarters, profit changed −21.3% and revenue +4.0%. Profit is growing slower than sales: rising costs are taking part of the growth. ## How much revenue does Jyothy Labs make, and is it growing? Jyothy Labs Ltd reported ₹773 Cr of revenue in the Jun 2026 quarter, +2.9% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 10 years it has grown 6.7% a year on average. The last full year, FY26, came in at ₹2,944 Cr. The last four reported quarters add to ₹2,966 Cr. FY26 revenue was ₹2,944 Cr, +3.5% on the year before. Recent pace: the last four quarters grew +4.0% on average, against 6.7% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +3.9%, against +2.8% a year over the last 8 quarters (stabilising); profit over the last 12 months grew −22.1%, against −12.8% a year (rolling over). ## How much of every ₹100 of sales does Jyothy Labs keep? Jyothy Labs Ltd's operating margin was 8.0% in the Jun 2026 quarter, 9.0 percentage points lower than the same quarter a year ago. Across 13 years it has been between 11.0% and 18.0%. The latest quarter is below every full year in that period. Why the margin moved: operating margin changed −8.2 percentage points on the year while gross margin changed −9.5 points. So the drop came mostly from the gross margin, which means input costs and prices charged. ## Is Jyothy Labs' profit turning into cash? Over the last 3 years, 110% of Jyothy Labs Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹412 Cr of operating cash against ₹333 Cr of profit. After ₹93.0 Cr of spending on assets, ₹319 Cr was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 110% of profit came in as cash: the cash cycle stayed about the same between FY21 and FY26, so the cash follows profit, not the cycle. What to look at next: no single use of cash stands out. The next section checks both the cash tied up in daily operations and the spending on assets. ## Where does Jyothy Labs' cash go? Jyothy Labs Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 38 days in FY26, down from 48 days in FY21. It spent ₹231 Cr on assets over the last 3 years. Customers take 32 days to pay, and stock sits for 80 days on average. At FY26 sales of ₹2,944 Cr, each day of that cycle ties up about ₹8.1 Cr, so roughly ₹306 Cr is tied up in the business at any time. FY26: customers took 32 days to pay and stock sat for 80 days, about 2.6 months of sales sitting as stock, for a full cycle of 38 days, shorter than FY21's 48. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 80 days. Customers pay about 32 days after that. Suppliers are paid at 74 days. Together that makes the 38-day cycle. Spending on assets: ₹231 Cr over the last 3 years, against ₹167 Cr of depreciation (the yearly wear and tear on existing assets). So it is building a little beyond replacing what wears out. Work still in progress is ₹10.0 Cr (FY26): assets paid for that are not earning yet. In short: neither the daily cycle nor new spending is soaking up the cash, so the picture is fairly clean. ## What is Jyothy Labs' P/E ratio, and how does it compare with its own history? Jyothy Labs Ltd's P/E is 24.3×, near the low end of its own history: it has been lower only 7% of the time. Its usual P/E (the middle reading) is 33.9×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved −10.3% while the price moved −40.1%. Earnings did better than the price, which pulled the multiple down within its own range. Where the price move came from: over 5 years the price moved +3.5% a year; about +7.4% a year came from earnings growth and about −3.9 percentage points from the multiple (the market paying less); over 10 years the price moved +0.8% a year; about +9.3% a year came from earnings growth and about −8.5 percentage points from the multiple (the market paying less). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is low against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Jyothy Labs business getting better or worse? Jyothy Labs Ltd's business is slowing from a peak. Profit and EPS growth have slowed sharply (profit growth from +73.4% at its peak to −22.1% now), while ROCE is still 24.5%. This is based on 12 quarters of 4 measures. Why it matters: slowing from a peak is where good stories often end quietly. ## How much does Jyothy Labs earn on its capital? Jyothy Labs Ltd earned a ROCE of 29% in FY26. That is up from a low of 11% in FY14. Its return on capital used (ROIC) is 17.8 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 11.3% net margin and 1.31× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 11.3% net margin × 1.31× asset turnover × 1.42× leverage (assets divided by equity) ≈ 21.0% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: 29.8% − 12.0% = +17.8 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. A gap this wide means each rupee put back into the business creates more than a rupee of value. The 29.8% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 38.8%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Jyothy Labs have too much debt? Jyothy Labs Ltd has total debt of ₹52.0 Cr against shareholder equity of ₹1,589 Cr as of Jun 2026, so its debt is 0.03× its equity, which is very little. Year by year, that ratio went from 0.12 in FY22 to 0.03 in FY26. So the returns on this page come from the business, not from borrowed money. ## What is the Jyothy Labs shareholding pattern? Domestic institutions cut their stake in Jyothy Labs Ltd by 5.4 percentage points over 8 quarters, the biggest change among its owners. Domestic institutions now own 9.9% of the company. Foreign institutions moved −0.6 points over the same period, to 14.5%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Domestic institutions: −5.4 points over 8 quarters, to 9.9%; Foreign institutions: −0.6 points over 8 quarters, to 14.5%; Promoters: +0.0 points over 8 quarters, to 62.9%. Why the owners changed: domestic institutions drove it (−5.4 points), together with foreign institutions (−0.6 points). They reduced their stake. ## How far is Jyothy Labs from balance-sheet trouble? For Jyothy Labs Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Jyothy Labs rank in its industry? 34.0 out of 100, rank 11 of 12 in FMCG - Personal Care, with 96% of the evidence available. Jyothy Labs Ltd scores 34.0 out of 100 against the 12 companies it is compared with in FMCG - Personal Care, ranking 11. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 6.7 + 13.9 + 7.7 + 5.7 = 34. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Jyothy Labs compared with? Jyothy Labs ranks 11 of 12 FMCG - Personal Care companies on the 4-Factor Sector Score, with 34.0 out of 100. 1. [Bajaj Consumer Care Ltd](https://www.sectoralpha.in/stocks/bajaj-consumer-care-ltd) BAJAJCON · quiet · Most evidence points up · 100% evidence 70.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 32.7/35 · Revenue 28% · Profit 84.6% · Operating margin change 7 points · 100% evidence Capital efficiency 19.2/25 · ROCE 30% · Operating margin 25% · 100% evidence Valuation 11.7/20 · P/E 19.3× · PEG 1.64 · 100% evidence Relative strength 6.5/20 · Lead over its industry 0.2% · Lead over NIFTY 500 -10.2% · 1 year 33.5% · 100% evidence · 0 of 12 weeks ahead Exact sum: 32.7 + 19.2 + 11.7 + 6.5 = 70.1 · What this means: Earnings are strong; relative strength in its sector is 0.2% and the one-year return is 33.5%. 2. [Hindustan Unilever Ltd](https://www.sectoralpha.in/stocks/hindustan-unilever-ltd) HINDUNILVR · basing · Most evidence points up · 100% evidence 69.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.4/35 · Revenue 9.5% · Profit 38% · Operating margin change -2 points · 100% evidence Capital efficiency 15.8/25 · ROCE 28.4% · Operating margin 22% · 100% evidence Valuation 17.2/20 · P/E 39.1× · PEG 0.72 · 100% evidence Relative strength 12.8/20 · Lead over its industry 1% · Lead over NIFTY 500 -9.9% · 1 year -21% · 100% evidence · 0 of 12 weeks ahead Exact sum: 23.4 + 15.8 + 17.2 + 12.8 = 69.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 3. [Marico Ltd](https://www.sectoralpha.in/stocks/marico-ltd) MARICO · quiet · Most evidence points up · 78% evidence 66.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.4/35 · Revenue 25.1% · Profit 15% · Operating margin change 1 points · 83% evidence Capital efficiency 17.9/25 · ROCE 47% · Operating margin 21% · 76% evidence Valuation 6.8/20 · P/E 55.1× · PEG n/a · 50% evidence Relative strength 17.4/20 · Lead over its industry 18.9% · Lead over NIFTY 500 6.5% · 1 year 11.2% · 100% evidence · 1 of 12 weeks ahead Exact sum: 24.4 + 17.9 + 6.8 + 17.4 = 66.5 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 4. [Gillette India Ltd](https://www.sectoralpha.in/stocks/gillette-india-ltd) GILLETTE · turning · Evidence leans up · 81% evidence 64.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.0/35 · Revenue 8% · Profit 18.4% · Operating margin change -1 points · 88% evidence Capital efficiency 18.1/25 · ROCE 90.7% · Operating margin 29% · 100% evidence Valuation 13.6/20 · P/E 34.5× · PEG 1.7 · 100% evidence Relative strength 10.1/20 · Lead over its industry n/a · Lead over NIFTY 500 -5.5% · 1 year -21.5% · 25% evidence · 0 of 12 weeks ahead Exact sum: 23 + 18.1 + 13.6 + 10.1 = 64.8 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Procter & Gamble Hygiene and Health Care Ltd](https://www.sectoralpha.in/stocks/procter-gamble-hygiene-and-health-care-ltd) PGHH · basing · Evidence leans up · 81% evidence 52.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 13.9/35 · Revenue -1.6% · Profit -4.7% · Operating margin change -9 points · 88% evidence Capital efficiency 17.6/25 · ROCE 157% · Operating margin 19% · 100% evidence Valuation 13.3/20 · P/E 28.1× · PEG 1.77 · 100% evidence Relative strength 7.5/20 · Lead over its industry n/a · Lead over NIFTY 500 -27.7% · 1 year -48.7% · 25% evidence · 0 of 12 weeks ahead Exact sum: 13.9 + 17.6 + 13.3 + 7.5 = 52.3 · What this means: The valuation scores well, but earnings are not improving yet, so the business does not back up the low multiple so far. 6. [Colgate-Palmolive (India) Ltd](https://www.sectoralpha.in/stocks/colgate-palmolive-indialtd) COLPAL · quiet · Evidence leans up · 85% evidence 51.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 12.5/35 · Revenue 8.7% · Profit 2.6% · Operating margin change -3 points · 100% evidence Capital efficiency 21.6/25 · ROCE 108% · Operating margin 28% · 100% evidence Valuation 8.4/20 · P/E 31.4× · PEG 6.07 · 100% evidence Relative strength 8.5/20 · Lead over its industry n/a · Lead over NIFTY 500 -17.1% · 1 year -28.8% · 25% evidence · 0 of 12 weeks ahead Exact sum: 12.5 + 21.6 + 8.4 + 8.5 = 51 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Dabur India Ltd](https://www.sectoralpha.in/stocks/dabur-india-ltd) DABUR · basing · Evidence leans up · 81% evidence 51.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 18.2/35 · Revenue 7.4% · Profit 10.9% · Operating margin change 0 points · 88% evidence Capital efficiency 14.9/25 · ROCE 20.3% · Operating margin 20% · 100% evidence Valuation 9.1/20 · P/E 32.7× · PEG 5.04 · 100% evidence Relative strength 8.8/20 · Lead over its industry n/a · Lead over NIFTY 500 -14.7% · 1 year -25% · 25% evidence · 0 of 12 weeks ahead Exact sum: 18.2 + 14.9 + 9.1 + 8.8 = 51 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Emami Ltd](https://www.sectoralpha.in/stocks/emami-ltd) EMAMILTD · basing · Evidence leans down · 96% evidence 43.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 9.0/35 · Revenue 2.8% · Profit -8.2% · Operating margin change -1 points · 88% evidence Capital efficiency 15.1/25 · ROCE 28.1% · Operating margin 22% · 100% evidence Valuation 8.9/20 · P/E 20.7× · PEG 2.99 · 100% evidence Relative strength 10.1/20 · Lead over its industry -3.2% · Lead over NIFTY 500 -13.6% · 1 year -32.7% · 100% evidence · 0 of 12 weeks ahead Exact sum: 9 + 15.1 + 8.9 + 10.1 = 43.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 9. [Zydus Wellness Ltd](https://www.sectoralpha.in/stocks/zydus-wellness-ltd) ZYDUSWELL · quiet · Evidence leans down · 96% evidence 39.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 12.8/35 · Revenue 66.3% · Profit -42.5% · Operating margin change -1 points · 88% evidence Capital efficiency 7.9/25 · ROCE 4.9% · Operating margin 17% · 100% evidence Valuation 6.0/20 · P/E 66.5× · PEG 1.75 · 100% evidence Relative strength 12.7/20 · Lead over its industry 12.9% · Lead over NIFTY 500 1.1% · 1 year -2.9% · 100% evidence · 2 of 12 weeks ahead Exact sum: 12.8 + 7.9 + 6 + 12.7 = 39.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [Godrej Consumer Products Ltd](https://www.sectoralpha.in/stocks/godrej-consumer-products-ltd) GODREJCP · quiet · Evidence leans down · 100% evidence 35.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 18.1/35 · Revenue 12.9% · Profit 8.6% · Operating margin change -1 points · 100% evidence Capital efficiency 10.3/25 · ROCE 18.8% · Operating margin 19% · 100% evidence Valuation 4.3/20 · P/E 39.4× · PEG 7.49 · 100% evidence Relative strength 2.9/20 · Lead over its industry -8.6% · Lead over NIFTY 500 -18.5% · 1 year -26.9% · 100% evidence · 0 of 12 weeks ahead Exact sum: 18.1 + 10.3 + 4.3 + 2.9 = 35.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 11. Jyothy Labs Ltd this page JYOTHYLAB · quiet · Most evidence points down · 96% evidence 34.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 6.7/35 · Revenue 3.9% · Profit -22.1% · Operating margin change -9 points · 88% evidence Capital efficiency 13.9/25 · ROCE 28.7% · Operating margin 8% · 100% evidence Valuation 7.7/20 · P/E 22.2× · PEG 5.24 · 100% evidence Relative strength 5.7/20 · Lead over its industry -11.6% · Lead over NIFTY 500 -21.2% · 1 year -45.3% · 100% evidence · 0 of 12 weeks ahead Exact sum: 6.7 + 13.9 + 7.7 + 5.7 = 34 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 12. [Polo Queen Industrial and Fintech Ltd](https://www.sectoralpha.in/stocks/polo-queen-industrial-and-fintech-ltd) PQIF · Too little evidence to rank firmly · 33% evidence 39.0 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [FMCG - Personal Care](https://www.sectoralpha.in/sectors/fmcg-personal-care), all 12 compared on one page. ## Which companies are close to Jyothy Labs in size? Jyothy Labs is the 10th largest of 12 FMCG - Personal Care companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Gillette India, Procter & Gamble Hygiene and Health Care, Emami and Zydus Wellness. Just below it: Bajaj Consumer Care and Polo Queen Industrial and Fintech. ### FMCG - Personal Care companies close in size

1. [Gillette India Ltd](https://www.sectoralpha.in/stocks/gillette-india-ltd) ₹23,064 crore
2. [Procter & Gamble Hygiene and Health Care Ltd](https://www.sectoralpha.in/stocks/procter-gamble-hygiene-and-health-care-ltd) ₹22,239 crore
3. [Emami Ltd](https://www.sectoralpha.in/stocks/emami-ltd) ₹15,703 crore
4. [Zydus Wellness Ltd](https://www.sectoralpha.in/stocks/zydus-wellness-ltd) ₹14,723 crore
5. Jyothy Labs Ltd ₹6,313 crore
6. [Bajaj Consumer Care Ltd](https://www.sectoralpha.in/stocks/bajaj-consumer-care-ltd) ₹4,835 crore
7. [Polo Queen Industrial and Fintech Ltd](https://www.sectoralpha.in/stocks/polo-queen-industrial-and-fintech-ltd) ₹638 crore

[All 12 FMCG - Personal Care companies, largest first](https://www.sectoralpha.in/sectors/fmcg-personal-care#all-companies)

### Companies close in size in other industries

1. [Kovai Medical Center & Hospital Ltd](https://www.sectoralpha.in/stocks/kovai-medical-center-hospital-ltd) ₹6,363 crore · Hospitals
2. [Gokul Agro Resources Ltd](https://www.sectoralpha.in/stocks/gokul-agro-resources-ltd) ₹6,329 crore · Edible Oils, Agro Processing
3. Jyothy Labs Ltd ₹6,313 crore
4. [IRB InvIT Fund](https://www.sectoralpha.in/stocks/irb-invit-fund) ₹6,312 crore · Infrastructure Investment Trusts
5. [Newgen Software Technologies Ltd](https://www.sectoralpha.in/stocks/newgen-software-technologies-ltd) ₹6,305 crore · IT Product Companies

## What else do people ask about Jyothy Labs? ### What is Jyothy Labs's share price today? Jyothy Labs Ltd's share price is ₹188.24, −40.1% over the past year. The whole company is worth ₹6,909 Cr on the market. In the last 52 weeks it traded between ₹172 to ₹312; today it is 12% of the way up from the low, 15.1% below its 200-day average (as of 3 November 2026). ### What were Jyothy Labs's latest quarterly results? Jyothy Labs Ltd reported revenue of ₹773 Cr and net profit of ₹48.0 Cr for the Jun 2026 quarter. Revenue rose 2.9% and profit fell 50.5% compared with a year earlier. Earnings per share were ₹1.30. The operating margin was 8.0%, 9.0 percentage points lower than a year earlier (as of 3 November 2026). ### What is Jyothy Labs's market cap? Jyothy Labs Ltd's market capitalisation is ₹6,909 Cr at a share price of ₹188.24. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Jyothy Labs performing? Jyothy Labs Ltd's share price has been falling for 99 weeks. In its latest quarter, revenue rose 2.9% and profit fell 50.5% compared with a year earlier. Over the past 13 weeks it has done worse than the NIFTY 500, for 4 weeks running (as of 3 November 2026). ### Will Jyothy Labs's share price go up? This page does not forecast Jyothy Labs Ltd's share price. What it shows instead: the share price is ₹188.24, and it has been falling for 99 weeks. Its P/E of 24.3× is higher than 7% of its own last 11 years (as of 3 November 2026). ### Does Jyothy Labs have too much debt? No, Jyothy Labs Ltd has little debt: its debt is 0.03× its equity, and its operating profit is 90 times its interest bill. FY26 borrowings were ₹52.0 Cr against equity of ₹1,589 Cr. So the returns on this page come from the business, not borrowed money (as of 3 November 2026). ### Where is Jyothy Labs in its business cycle? Jyothy Labs Ltd's FY26 operating margin was 15.0%, against a 13-year range of 11.0% to 18.0%: the middle of its own range, neither a peak nor a low. The latest quarter was 8.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Jyothy Labs story? The main question: yearly earnings per share moved −10.3% while the share price moved −40.1%. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Jyothy Labs a stock worth studying right now? What the numbers show: Jyothy Labs Ltd's P/E is near the low end of its own history, higher than only 7% of past readings, and its quarterly results are still getting worse. The main open question: whether the price catches up with earnings that have already grown. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). ### Is there a Jyothy Labs share price forecast for 2026? What management itself guided: FY27 revenue excluding Pril/Fa expected to grow double digit. ## Lists

- 52 week high & low: https://www.sectoralpha.in/52-week-high-stocks-india
- Dividend stocks: https://www.sectoralpha.in/dividend-stocks-india

This is research, not advice. We’re not SEBI-registered.